Atrial fibrillation (AF) is a common and significant concern in multiple myeloma patients, especially around the time of autologous stem cell transplantation (ASCT). Studies show that AF can occur in up to 27% of MM patients after ASCT, often within the first few weeks, and is linked to factors like baseline heart function, kidney health, and hypertension
. While your echocardiogram shows little structural heart disease, AF itself increases the risk of complications during transplantation.
Because ASCT carries a higher risk of cardiovascular events, including AF, many doctors carefully assess heart health before recommending it
. Your history of AF episodes-even if infrequent-may lead your consultant to be cautious, as AF can worsen with the stress of transplant and conditioning treatments, potentially impacting your safety and outcomes
.
That said, decisions about ASCT are individualized. If your AF is well-controlled and your overall cardiac function is good, some centers may still consider transplant with close monitoring and preventive strategies. It’s important to discuss with your hematologist and cardiologist about managing AF risks and whether ASCT can be safely pursued in your case.